消瘀接骨散外敷治疗早中期膝骨关节炎30例临床研究
Clinical Effect of External Application of Xiaoyu Jiegu Powder in Treatment of Early-to-Mid Knee Osteoarthritis: An Analysis of 30 Cases
  
DOI:
中文关键词:  膝骨关节炎  消瘀接骨散  塞来昔布
英文关键词:Knee osteoarthritis  Xiaoyu Jiegu Powder  Celecoxib
基金项目:安徽省高校省级自然科学研究项目(KJ2012Z215)
作者单位
王 正,刘安平,梁文武,王 峰,周正新,张建华 安徽中医药大学第一附属医院骨伤科安徽 合肥 230031 
摘要点击次数: 1218
全文下载次数: 1729
中文摘要:
      目的 观察消瘀接骨散外敷治疗早中期膝骨关节炎的临床疗效。方法 将60例膝骨关节炎患者随机分成观察组(外敷消瘀接骨散)和对照组(口服塞来昔布胶囊),每组30例。治疗2周后连续随访12周,比较两组临床疗效,观察治疗前后血沉(erythrocyte sedimentation rate, ESR)、碱性磷酸酶(alkaline phosphatase, ALP)、高敏C-反应蛋白(hypersensitive C-reactive protein,hs-CRP)、血小板(platelet,PLT)及疼痛视觉模拟评分(visual analogue scale,VAS)、西安大略和麦克马斯特大学骨关节炎指数(Western Ontario McMaster University Osteoarthritis Index, WOMAC)、骨关节炎的严重程度指数(Lequesne MG)、膝关节活动度变化情况。结果 观察组临床疗效优于对照组,但两组临床疗效的分布比较,差异无统计学意义(P>0.05)。观察组治疗后hs-CRP、ALP、PLT较治疗前显著降低,差异均有统计学意义(P<0.05);观察组PLT降低值显著大于对照组(P<0.05)。两组患者治疗后WOMAC、VAS、Lequesne MG评分均较治疗前显著降低(P<0.05),膝关节活动度较治疗前显著增加(P<0.05);与治疗2周末比较,两组患者随访时WOMAC、VAS、Lequesne MG评分均无明显变化(P>0.05),但膝关节活动度显著增加(P<0.05)。治疗2周末和随访时,观察组患者WOMAC、VAS、Lequesne MG评分显著低于对照组(P<0.05);治疗2周末,观察组患者膝关节活动度显著大于对照组(P<0.05);随访时,两组患者膝关节活动度比较,差异无统计学意义(P>0.05)。结论 消瘀接骨散外敷治疗轻中度膝骨关节炎可显著改善临床症状和膝关节功能,提高患者生活质量。
英文摘要:
      Objective To investigate the clinical effect of external application of Xiaoyu Jiegu Powder in the treatment of early-to-mid knee osteoarthritis. Methods A total of 60 patients with knee osteoarthritis were randomly divided into observation group (treated with external application of Xiaoyu Jiegu Powder) and control group (treated with oral celecoxib capsules), with 30 patients in each group. The patients were followed up for 12 weeks after 2 weeks of treatment, and the two groups were compared in terms of clinical outcome and the changes in related indices after treatment, including erythrocyte sedimentation rate (ESR), alkaline phosphatase (ALP), hypersensitive C-reactive protein (hs-CRP), platelet count (PLT), Visual Analogue Scale (VAS) score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne MG score for the severity of osteoarthritis. Results The observation group had a better clinical outcome than the control group, and there was no significant difference in the distribution of clinical outcomes between the two groups (P>0.05). The observation group had significant reductions in hs-CRP, ALP, and PLT after treatment (P<0.05), and the observation group had a significantly greater reduction in PLT than the control group (P<0.05). Both groups had significant reductions in WOMAC, VAS, and Lequesne MG scores and a significant increase in the range of motion of the knee joint after treatment (P<0.05). There were no significant changes in WOMAC, VAS, and Lequesne MG scores from the end of the 2-week treatment to follow-up (P>0.05), but there was a significant increase in the range of motion of the knee joint (P<0.05). At the end of the 2-week treatment and during follow-up, the observation group had significantly lower WOMAC, VAS, and Lequesne MG scores than the control group (P<0.05); at the end of the 2-week treatment, the observation group had a significantly higher range of motion of the knee joint than the control group (P<0.05); during follow-up, there was no significant difference in the range of motion of the knee joint between the two groups (P>0.05). Conclusion External application of Xiaoyu Jiegu Powder has a good clinical effect in the treatment of early-to-mid knee osteoarthritis and can significantly improve clinical symptoms, knee function, and patients' quality of life.
查看全文  查看/发表评论  下载PDF阅读器
关闭